Mereo BioPharma(US:MREO) Prnewswire·2026-02-11 14:40Core Viewpoint - Mereo BioPharma Group plc is facing a securities class action lawsuit due to alleged violations of federal securities laws related to misleading statements about its Phase 3 clinical trials, which failed to meet primary endpoints [1][1]. Group 1: Legal Action and Deadlines - Faruqi & Faruqi, LLP is investigating claims against Mereo BioPharma and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in the class action [1]. - The lawsuit alleges that Mereo and its executives made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs [1][1]. Group 2: Clinical Trial Results - Mereo announced on December 29, 2025, that two Phase 3 studies of setrusumab did not meet their primary endpoints of reducing annualized clinical fracture rates compared to placebo and bisphosphonates [1][1]. - Despite showing statistically significant improvements in bone mineral density on secondary endpoints, the failure to meet primary endpoints led to a negative market reaction [1]. Group 3: Stock Price Impact - Following the announcement of the failed trials, Mereo's stock price dropped by $2.02 per share, representing an 87.64% decline, closing at $0.28 per share on December 29, 2025 [1][1].